Skip to main content
Erschienen in: Current Pulmonology Reports 2/2013

01.06.2013 | Pleural Diseases and Mesothelioma (YCG Lee, Section Editor)

EGFR mutations in malignant pleural effusions from lung cancer

verfasst von: Clayton J. Shamblin, Nichole T. Tanner, Rolando Sanchez Sanchez, Julie A. Woolworth, Gerard A. Silvestri

Erschienen in: Current Pulmonology Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

A malignant pleural effusion (MPE) from lung cancer represents stage IV disease and portends a poor prognosis. Routine mutational analysis of tissue samples is the standard of care in advanced lung cancer management because it has treatment implications. Sampling of MPE is minimally invasive, safe, repeatable, and provides both diagnostic and therapeutic value. Mutational analysis on MPE has been shown to be feasible and correlates with a response to targeted therapy with tyrosine kinase inhibitors (TKIs). Guidelines recommend mutational testing in MPE, however there is no one standardized method for testing. There are several testing methods available for mutational analysis in pleural fluid including PCR, mutant-enriched PCR, DNA & RNA sequencing, and immunohistochemistry the sensitivity of which are dependent upon tumor cell heterogeneity. The advantages and disadvantages of each will be reviewed here.
Literatur
1.
Zurück zum Zitat Cancer facts and figures. Atlanta, GA: American Cancer Society; 2012 Cancer facts and figures. Atlanta, GA: American Cancer Society; 2012
2.
Zurück zum Zitat Network. NCC. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V.2.2012; 2012 Network. NCC. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V.2.2012; 2012
3.
Zurück zum Zitat Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113–20.PubMedCrossRef Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113–20.PubMedCrossRef
4.
Zurück zum Zitat Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268–75.PubMedCrossRef Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268–75.PubMedCrossRef
5.
Zurück zum Zitat Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744–52.PubMedCrossRef Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744–52.PubMedCrossRef
6.
Zurück zum Zitat • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57. This study is the first to show that EGFR mutations in NSCLC are associated with favorable responses to TKI therapy.PubMedCrossRef • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57. This study is the first to show that EGFR mutations in NSCLC are associated with favorable responses to TKI therapy.PubMedCrossRef
7.
Zurück zum Zitat Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394–400.PubMedCrossRef Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394–400.PubMedCrossRef
8.
Zurück zum Zitat Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 2000;117:79–86.PubMedCrossRef Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 2000;117:79–86.PubMedCrossRef
9.
Zurück zum Zitat Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef
10.
Zurück zum Zitat Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J. 1997;10:1907–13.PubMedCrossRef Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J. 1997;10:1907–13.PubMedCrossRef
11.
Zurück zum Zitat Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92.PubMedCrossRef Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92.PubMedCrossRef
12.
Zurück zum Zitat Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893–903.PubMedCrossRef Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893–903.PubMedCrossRef
13.
Zurück zum Zitat Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6:957–65.PubMed Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6:957–65.PubMed
14.
Zurück zum Zitat Shen YC, Liu MQ, Wan C, et al. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: a meta-analysis. Exp Ther Med. 2012;3:1072–6.PubMed Shen YC, Liu MQ, Wan C, et al. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: a meta-analysis. Exp Ther Med. 2012;3:1072–6.PubMed
15.
Zurück zum Zitat Marshall HM, Leong SC, Bowman RV, et al. The science behind the 7th edition tumour, node, metastasis staging system for lung cancer. Respirology. 2012;17:247–60.PubMedCrossRef Marshall HM, Leong SC, Bowman RV, et al. The science behind the 7th edition tumour, node, metastasis staging system for lung cancer. Respirology. 2012;17:247–60.PubMedCrossRef
16.
Zurück zum Zitat Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol. 2008;3:216–27.PubMedCrossRef Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol. 2008;3:216–27.PubMedCrossRef
17.
Zurück zum Zitat Morgensztern D, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7:1485–9.PubMedCrossRef Morgensztern D, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7:1485–9.PubMedCrossRef
18.
Zurück zum Zitat Wu SG, Yu CJ, Tsai MF, et al. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 2012; Wu SG, Yu CJ, Tsai MF, et al. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 2012;
19.
Zurück zum Zitat Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121–7.PubMedCrossRef Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121–7.PubMedCrossRef
20.
Zurück zum Zitat Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.PubMedCrossRef Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.PubMedCrossRef
21.
Zurück zum Zitat Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54–9.PubMedCrossRef Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54–9.PubMedCrossRef
22.
Zurück zum Zitat Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol. 2009;4:S283–4. Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol. 2009;4:S283–4.
23.
Zurück zum Zitat Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.PubMedCrossRef Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.PubMedCrossRef
24.
Zurück zum Zitat Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.PubMedCrossRef Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.PubMedCrossRef
25.
Zurück zum Zitat Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol. 30. 2012; (suppl; abstr 7521) 2012. Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol. 30. 2012; (suppl; abstr 7521) 2012.
26.
Zurück zum Zitat • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. This study highlights the importance of routine testing for EGFR mutations with advanced NSCLC and first-line therapy with TKIs.PubMedCrossRef • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. This study highlights the importance of routine testing for EGFR mutations with advanced NSCLC and first-line therapy with TKIs.PubMedCrossRef
27.
Zurück zum Zitat Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.PubMedCrossRef Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.PubMedCrossRef
28.
Zurück zum Zitat Yang JC, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. 2012; supp 30:abstr LBA7500 Yang JC, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. 2012; supp 30:abstr LBA7500
29.
Zurück zum Zitat Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151:238–41.PubMedCrossRef Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol. 2004;151:238–41.PubMedCrossRef
30.
Zurück zum Zitat Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–9.PubMedCrossRef Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–9.PubMedCrossRef
31.
Zurück zum Zitat Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef
32.
Zurück zum Zitat Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–60.PubMedCrossRef Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–60.PubMedCrossRef
33.
Zurück zum Zitat Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–501.PubMedCrossRef Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–501.PubMedCrossRef
34.
Zurück zum Zitat Costa DB, Schumer ST, Tenen DG, et al. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008;26:1182–4. author reply 1184–1186.PubMedCrossRef Costa DB, Schumer ST, Tenen DG, et al. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol. 2008;26:1182–4. author reply 1184–1186.PubMedCrossRef
35.
Zurück zum Zitat Belalcazar A, Azana D, Perez CA, et al. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther. 2012;12:519–28.PubMedCrossRef Belalcazar A, Azana D, Perez CA, et al. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther. 2012;12:519–28.PubMedCrossRef
36.
Zurück zum Zitat Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26:983–94.PubMedCrossRef Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26:983–94.PubMedCrossRef
37.
Zurück zum Zitat Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32:924–30.PubMedCrossRef Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32:924–30.PubMedCrossRef
38.
Zurück zum Zitat Froudarakis ME. Pleural effusion in lung cancer: more questions than answers. Respiration. 2012;83:367–76.PubMedCrossRef Froudarakis ME. Pleural effusion in lung cancer: more questions than answers. Respiration. 2012;83:367–76.PubMedCrossRef
39.
Zurück zum Zitat Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 2006;12:43–8.PubMedCrossRef Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 2006;12:43–8.PubMedCrossRef
40.
Zurück zum Zitat Hung MS, Lin CK, Leu SW, et al. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J. 2006;29:373–9.PubMed Hung MS, Lin CK, Leu SW, et al. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J. 2006;29:373–9.PubMed
41.
Zurück zum Zitat Jian G, Songwen Z, Ling Z, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:1341–7.PubMedCrossRef Jian G, Songwen Z, Ling Z, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:1341–7.PubMedCrossRef
42.
Zurück zum Zitat Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006;97:642–8.PubMedCrossRef Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006;97:642–8.PubMedCrossRef
43.
Zurück zum Zitat Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006;95:1390–5.PubMedCrossRef Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006;95:1390–5.PubMedCrossRef
44.
Zurück zum Zitat Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006;119:2353–8.PubMedCrossRef Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006;119:2353–8.PubMedCrossRef
45.
Zurück zum Zitat Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci. 2007;98:246–52.PubMedCrossRef Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci. 2007;98:246–52.PubMedCrossRef
46.
Zurück zum Zitat Tsai TH, Su KY, Wu SG, et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J. 2012;39:677–84.PubMedCrossRef Tsai TH, Su KY, Wu SG, et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J. 2012;39:677–84.PubMedCrossRef
47.
Zurück zum Zitat Zhang X, Zhao Y, Wang M, et al. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer. 2008;60:175–82.PubMedCrossRef Zhang X, Zhao Y, Wang M, et al. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer. 2008;60:175–82.PubMedCrossRef
49.
Zurück zum Zitat Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:131S–48S.PubMedCrossRef Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:131S–48S.PubMedCrossRef
50.
Zurück zum Zitat Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556–68.PubMedCrossRef Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556–68.PubMedCrossRef
51.
Zurück zum Zitat Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.PubMedCrossRef Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.PubMedCrossRef
52.
Zurück zum Zitat Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13:e23–31.PubMedCrossRef Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13:e23–31.PubMedCrossRef
53.
Zurück zum Zitat Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol. 2005;2:554–61.PubMedCrossRef Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol. 2005;2:554–61.PubMedCrossRef
54.
Zurück zum Zitat Huang MJ, Lim KH, Tzen CY, et al. EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report. Lung Cancer. 2005;49:413–5.PubMedCrossRef Huang MJ, Lim KH, Tzen CY, et al. EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report. Lung Cancer. 2005;49:413–5.PubMedCrossRef
55.
Zurück zum Zitat Soh J, Toyooka S, Ichihara S, et al. EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer. 2007;56:445–8.PubMedCrossRef Soh J, Toyooka S, Ichihara S, et al. EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer. 2007;56:445–8.PubMedCrossRef
56.
Zurück zum Zitat Tsai TH, Wu SG, Chang YL, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol. 2012;7:993–1000.PubMedCrossRef Tsai TH, Wu SG, Chang YL, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol. 2012;7:993–1000.PubMedCrossRef
57.
Zurück zum Zitat • Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:380–6. This study showed a discordance between EGFR mutation status in primary and metastatic sites in a significant number of lung adenocarcinomas, and highlights the importance of repeat sampling for mutational analysis in such cases.PubMedCrossRef • Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12:380–6. This study showed a discordance between EGFR mutation status in primary and metastatic sites in a significant number of lung adenocarcinomas, and highlights the importance of repeat sampling for mutational analysis in such cases.PubMedCrossRef
58.
Zurück zum Zitat Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer. 2009;117:67–72.PubMed Smouse JH, Cibas ES, Janne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer. 2009;117:67–72.PubMed
59.
Zurück zum Zitat Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012;76:1–18.PubMedCrossRef Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012;76:1–18.PubMedCrossRef
60.
Zurück zum Zitat Buttitta F, Felicioni L, Del Grammastro M, et al. Effective Assessment of Egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next Generation Sequencing. Clin Cancer Res. 2012; Buttitta F, Felicioni L, Del Grammastro M, et al. Effective Assessment of Egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next Generation Sequencing. Clin Cancer Res. 2012;
61.
Zurück zum Zitat Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12:852–5.PubMedCrossRef Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12:852–5.PubMedCrossRef
62.
Zurück zum Zitat Querings S, Altmuller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One. 2011;6:e19601.PubMedCrossRef Querings S, Altmuller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One. 2011;6:e19601.PubMedCrossRef
63.
Zurück zum Zitat Liu Y, Liu B, Li XY, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res. 2011;30:111.PubMedCrossRef Liu Y, Liu B, Li XY, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res. 2011;30:111.PubMedCrossRef
64.
Zurück zum Zitat Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023–8.PubMedCrossRef Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023–8.PubMedCrossRef
65.
Zurück zum Zitat Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12:169–76.PubMedCrossRef Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12:169–76.PubMedCrossRef
66.
Metadaten
Titel
EGFR mutations in malignant pleural effusions from lung cancer
verfasst von
Clayton J. Shamblin
Nichole T. Tanner
Rolando Sanchez Sanchez
Julie A. Woolworth
Gerard A. Silvestri
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Pulmonology Reports / Ausgabe 2/2013
Elektronische ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-013-0041-5

Weitere Artikel der Ausgabe 2/2013

Current Pulmonology Reports 2/2013 Zur Ausgabe

Sleep Medicine (V Castronovo, Section Editor)

Sleep-disordered breathing in pregnancy

Pleural Diseases and Mesothelioma (YCG Lee, Section Editor)

Management options for the complicated pleural space

Pleural Diseases and Mesothelioma (YCG Lee, Section Editor)

Prognostic factors for malignant pleural mesothelioma

Sleep Medicine (V Castronovo, Section Editor)

Chronic obstructive pulmonary disease and sleep

Pleural Diseases and Mesothelioma (YCG Lee, Section Editor)

Advantages of indwelling pleural catheters for management of malignant pleural effusions

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.